glp·helper
glphelper.com/wegovy/florida/cape-coral
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Cape Coral, FL

Verified Wegovy providers in Cape Coral, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
24
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
25 of 25 shown

Find an Wegovy provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /wegovy/florida/{city}
§ 03Getting Wegovy in Cape Coral
25 providers · Cape Coral, FL

How to get Wegovy in Cape Coral.

25 GLP-1 prescribers and 7 local resource types are on record for Cape Coral, plus 3 nearby towns in the directory.

Prescribers in Cape Coral
25 prescribers
25 GLP-1 prescribers in Cape Coral, most listed as Family Medicine (12), Internal Medicine (9) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Fort Myers (31 providers), Port Charlotte (30 providers) and North Port (28 providers).
Around the prescription in Cape Coral
7 listed nearby
28 dietitians, 10 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Cape Coral.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Cape Coral

Cape Coral, Florida has a population of 194,016 people. The adult obesity rate in Cape Coral is an age-adjusted estimate of 30.4%, 0.8 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 10.2% of adults in Cape Coral. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.5% of adults in Cape Coral.

of Cape Coral adults have obesity
30.4%
diagnosed diabetes
10.2%
no regular physical activity
23.5%

Age-adjusted estimates for Cape Coral, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Wegovy in Cape Coral
6 dietitians

The prescription is one part. Here is the rest, in Cape Coral.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Cape Coral, FL, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Janice Anderson, R.D., LDN
RD
Registered dietitian
543 Se 33Rd Terrace
Call 239-549-0552NPI 1679795959
Brittany Chambers, RDN, LDN, CPT
RD
Registered dietitian
501 Del Prado Blvd S
Call 630-779-7610NPI 1144864638
Kelly Derwick, RDN, LN
RD
Registered dietitian
119 Se 39Th St
Call 239-910-3871NPI 1033715727
Stephanie Fry, RN, RD, LDN, CDCES
RD
Registered dietitian
4417 Agualinda Blvd
Call 239-469-0866NPI 1336978576
Joanna Hill, RD
RD
Registered dietitian
2211 Nw 7Th Pl
Call 239-961-0442NPI 1538876727
Alyson Hornby, RDN, LDN
RD
Registered dietitian
501 Del Prado Blvd S
Call 239-424-3120NPI 1295598712

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tina Anderson, RD,LDN, MPH, CDE
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1235536293
Melanie Aracri, RD LD CDE
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1477524650
Erika Graziani, M.S., R.D., L.D
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1316132699
Alayna Horvath, RD, RDN
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1245843622
Timothy Katz, RD, CDCES
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1588431423
Jessica Quigley, RD, CDE
NUTRITIONIST
Nutritionist
501 Del Prado Blvd S
Call 239-424-3120NPI 1255939922
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in Florida

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]